دورية أكاديمية
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials.
| العنوان: | Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. |
|---|---|
| المؤلفون: | Choderlos de Laclos X; Oncology Department, Eugène Marquis Centre, Avenue de la Bataille Flandres-Dunkerque, Rennes, France. Electronic address: x.choderlos-de-laclos@rennes.unicancer.fr., Risbourg S; Methodology and Biostatistics Unit, Oscar Lambret Centre, 3 Rue Frédéric Combemale, Lille, France. Electronic address: s-risbourg@o-lambret.fr., Brennan B; Department of paediatric oncology, Royal Manchester Children's Hospital, Manchester, UK. Electronic address: Bernadette.Brennan@mft.nhs.uk., Bertucci F; Department of Medical Oncology, Paoli-Calmettes Institute, Aix-Marseille Université, 232 Boulevard de Sainte-Marguerite, Marseille, France. Electronic address: BERTUCCIF@ipc.unicancer.fr., Gaspar N; Department of Oncology for Child and adolescent, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France. Electronic address: Nathalie.GASPAR@gustaveroussy.fr., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, The Netherlands. Electronic address: a.j.gelderblom@lumc.nl., Hawkins DS; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. Electronic address: doug.hawkins@seattlechildrens.org., Janeway K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA. Electronic address: Katherine_Janeway@dfci.harvard.edu., Juergens H; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Germany, West German Cancer Centre (WTZ) Network, Muenster, Germany. Electronic address: jurgh@ukmuenster.de., Kasper B; University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC), Sarcoma Unit, Mannheim, Germany. Electronic address: Bernd.Kasper@medma.uni-heidelberg.de., Krailo MD; University of Southern California, Los Angeles, CA, USA. Electronic address: mkrailo@childrensoncologygroup.org., Cécile Le Deley M; Methodology and Biostatistics Unit, Oscar Lambret Centre, 3 Rue Frédéric Combemale, Lille, France. Electronic address: m-ledeley@o-lambret.fr., Marec-Bérard P; Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, 28 Prom. Léa et Napoléon Bullukian, Lyon, France. Electronic address: perrine.marec-berard@ihope.fr., McCabe MG; Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust, Manchester, UK. Electronic address: Martin.McCabe@manchester.ac.uk., Metzler M; Department of Pediatrics, University Hospital Erlangen, and NCT WERA, Erlangen, Germany. Electronic address: Markus.Metzler@uk-erlangen.de., Ranft A; Pediatrics III, University Hospital Essen, Essen, Germany, West German Cancer Centre (WTZ), German Consortium for Translational Cancer Research (DKTK), and National Center for Tumordiseases site Essen, Essen, Germany. Electronic address: Andreas.ranft@uk-essen.de., Strauss S; London Sarcoma Service, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: sandra.strauss@nhs.net., Tabone MD; Pediatric Hematology and Oncology Department, Armand Trousseau Hospital, AP-HP, Sorbonne University, 26 avenue du Docteur Arnold-Netter, Paris, France. Electronic address: marie-dominique.tabone@aphp.fr., Windsor R; London Sarcoma Service, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: rachael.windsor@nhs.net., Dirksen U; Pediatrics III, University Hospital Essen, Essen, Germany, West German Cancer Centre (WTZ), German Consortium for Translational Cancer Research (DKTK), and National Center for Tumordiseases site Essen, Essen, Germany. Electronic address: Uta.Dirksen@uk-essen.de., Gandemer V; Department of Pediatric Onco-hematology, University Hospital, 16 Bd de Bulgarie, Rennes, France. Electronic address: virginie.gandemer@chu-rennes.fr. |
| المصدر: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Sep; Vol. 208, pp. 114229. Date of Electronic Publication: 2024 Jul 15. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Elsevier Science Ltd Original Publication: Oxford ; New York : Pergamon Press, c1990- |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*/methods , Hematopoietic Stem Cell Transplantation*/adverse effects , Sarcoma, Ewing*/drug therapy , Sarcoma, Ewing*/therapy , Busulfan*/administration & dosage , Busulfan*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Transplantation, Autologous* , Melphalan*/administration & dosage , Melphalan*/adverse effects , Melphalan*/therapeutic use, Humans ; Child ; Adolescent ; Young Adult ; Male ; Female ; Age Factors ; Adult ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Vincristine/adverse effects ; Vincristine/administration & dosage ; Vincristine/therapeutic use ; Child, Preschool ; Ifosfamide/administration & dosage ; Ifosfamide/adverse effects ; Treatment Outcome |
| مستخلص: | Introduction: Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved outcomes in unfavourable localized ES, but with more toxicities than conventional chemotherapy (VAI: Vincristine-dactinomycin-Ifosfamide). We evaluated whether the risk of acute toxicity associated with BuMel compared to VAI varied according to age in patients recruited in the R2Loc and R2Pulm randomised trials of the Euro-E.W.I.N.G.99 and Ewing-2008 trials. Methods: We included patients with a localized high-risk disease, or pulmonary or pleural metastasis. We analysed the risk of severe toxicity according to randomised treatment group (VAI versus BuMel) and age group (<12 years, 12-17 years, 18-24 years, ≥25 years). We evaluated the heterogeneity of treatment effects by age group using interaction terms in logistic multivariable models. Results: The analysis included 243 patients treated with VAI and 205 with BuMel. Overall, BuMel was associated with a higher risk of severe acute toxicity than VAI particularly haematological, gastrointestinal, liver, sinusoidal occlusive syndrome, and infections. Severe haematological toxicity and lower general condition were significantly more frequent in younger patients, whatever treatment. We did not observe any significant heterogeneity in terms of the excess risk of severe toxicities associated with BuMel compared to VAI according to age group. Conclusion: The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| معلومات مُعتمدة: | U10 CA180899 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Autologous hematopoietic stem cells transplantation; Ewing sarcoma (ES); High dose chemotherapy; Safety |
| المشرفين على المادة: | G1LN9045DK (Busulfan) Q41OR9510P (Melphalan) 6PLQ3CP4P3 (Etoposide) 5J49Q6B70F (Vincristine) UM20QQM95Y (Ifosfamide) |
| تواريخ الأحداث: | Date Created: 20240720 Date Completed: 20240810 Latest Revision: 20240813 |
| رمز التحديث: | 20240813 |
| DOI: | 10.1016/j.ejca.2024.114229 |
| PMID: | 39032218 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0852 |
|---|---|
| DOI: | 10.1016/j.ejca.2024.114229 |